Uses AI and automated biology experiments to discover and develop new drugs across multiple disease areas.
Uses AI and automated biology experiments to discover and develop new drugs across multiple disease areas.
Pays for research mainly from investor capital and from partners such as Roche and Sanofi, who make upfront and milestone payments tied to drug programs reaching defined stages; no product is on sale. It combined with Exscientia in 2024 to add chemistry design to its biology data.
Moat: narrow (data, IP / patents, process know-how). Massive proprietary biological/chemical dataset from automated wet-lab experiments feeds AI models.
Headquarters: Salt Lake City, Utah, US · Founded: 2013 · Employees: 600
Size Recursion Pharmaceuticals (RXRX) is a United States Health Care company (Biotechnology) with a market value of $1.76B, the 1859th largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.83 on 18 Nov 2026.
Performance Over six months the shares fell 4.6%, against -2.7% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 56.2% over the last twelve months (peer median +10.8%); the operating margin is -725.4% (peer median -8.7%).
Valuation It trades at 18.8× enterprise value to sales against a peer median of 11.7× (5th most expensive of 16).
Capital Return on invested capital runs 102.8 points below its cost of capital (10.6% WACC).
Short interest Short interest is 22.8% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $68.2M | $74.7M | $58.8M | $44.6M | $39.8M |
| Revenue growth | — | +27% | +32% | +12% | — |
| Gross profit | -$27.3M | -$46.3M | -$4.59M | -$6.51M | -$8.81M |
| EBITDA | -$421M | -$564M | -$443M | -$318M | -$226M |
| Net income | -$476M | -$645M | -$464M | -$328M | -$239M |
| Free cash flow | -$312M | -$378M | -$373M | -$300M | -$121M |
| Capital expenditure | $3.95M | $8.63M | $17.0M | $12.6M | $37.4M |
| Total debt | $74.7M | $78.0M | $108M | $50.7M | $51.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals RXRX | $1.76B | -5% | +56% | -725% | 18.8× | n/a |
| Schrodinger SDGR | $2.04B | +127% | +5% | -50% | 6.6× | n/a |
| Relay Therapeutics RLAY | $3.65B | +27% | +24% | -3,095% | 273.1× | n/a |
| XtalPi 2228.HK | $2.87B | -34% | +4% | -127% | 21.3× | n/a |
| Absci ABSI | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RXRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.8% | -1.1% | 2nd lowest of 20 |
| 6-month return | -4.6% | -2.7% | 9th lowest of 20 |
| Distance from 52-week high | -46.1% | -33.4% | 4th lowest of 21 |
| Revenue growth (TTM) | +56.2% | +10.8% | 4th highest of 16 |
| Operating margin | -725.4% | -8.7% | 5th lowest of 17 |
| EV / Sales | 18.8× | 11.7× | 5th most expensive of 16 |
| ROIC minus cost of capital | -102.8 pp | -4.4 pp | lowest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | 18.8× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | 50.6× | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 11.7× | 33.0% | +24.8% |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 3.6× | -12.1% | +15.0% |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | 149.9× | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 4.9× | 22.7% | +3.4% |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 4.2× | n/a | n/a |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 1.7× | -7.6% | +33.5% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 6.4× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 14.4× | 33.2% | +16.8% |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | 1,650.2× | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |